<DOC>
	<DOCNO>NCT00928798</DOCNO>
	<brief_summary>The purpose study determine whether topical application rapamycin lead reduction size and/or number fibrofolliculomas BHD patient may prevent growth new one . Secondary evaluate rapamycin safety , formula acceptance patient satisfaction .</brief_summary>
	<brief_title>Topical Rapamycin Fibrofolliculomas</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Birt-Hogg-Dube Syndrome</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Minimum age 18 year . At least 10 facial fibrofolliculomas , histologically confirm . Entered screen program free malignancy determine screen ( already baseline MRI CTscan ) . Being able understand instruction . Mutation status must know . For female : pregnant willing use oral barrier contraceptive treatment period . Not capable informed consent . Age 18 year . Pregnancy failure comply contraceptive measure . Proven suspect malignancy skin organ . No histological confirmation . Skin lesion fibrofolliculoma might worsen sirolimus active infection . Not able comprehend instruction . No proven mutation . Less 10 fibrofolliculomas . Planned facial surgery treatment period . Concomitant disease require systemic immunosuppressive treatment Concomitant disease require facial topical immunosuppressive treatment facial topical drug interfere rapamycin trail period 30 day start trial . Tendency form keloid hypertrophic scar . Drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>